We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Immediate Diagnosis Provided at POC for Cardiac Patients

By HospiMedica International staff writers
Posted on 12 Oct 2009
A new biochip analyzer will help save cardiac patients lives by providing immediate diagnosis at the point of care (POC). More...
The technology is based on the concept of using a biochip as a reaction platform with multiple specific ligands (antibodies and antigens) attached at pre-defined sites on the surface.

The Evidence MultiStat biochip analyzer is a product of Randox (Crumlin, UK). In addition to cardiac tests, it offers arrays for stroke, metabolic syndrome, cancer, fertility disorders, thyroid disorders, synthetic steroids, and drugs of abuse. The Evidence MutiStat belongs to a family of flexible and reliable immunoassay analyzers. The largest member of the family is the Evidence, which has an output of 1,400 tests per hour.

The MutiStat system is suitable for emergency departments, cardiac units, doctor's surgeries, forensic units, rehabilitation units, and employee drug screening centers. The technology offers fully automated pipetting, incubation, washing, imaging, and report generation. This, together with a user-friendly touch screen and Windows-based software, enables the MultiStat to be used by nontechnical staff with little or no training.

The test menu can work with a wide range of sample matrix including urine and serum--plasma and whole blood are currently in development. The cardiac arrays include creatinine kinase-MB (CK-MB), fatty acid binding protein (FABP), myoglobin, and cardiac troponin. The drugs of abuse arrays include multiple analytes such as amphetamine, barbiturates, benzadiazepine, cannabinoids, and cocaine.

Cardiovascular disease is a progressive and complicated condition, covering a range of symptoms and biochemical processes that vary according to the patient. Multiple markers are therefore required to provide accurate diagnoses. The new Randox technology benefits patients with chest pains by rapidly identifying risk and enabling accurate clinical decisions.

Randox is a diagnostics company that develops, manufactures, and markets clinical diagnostic products worldwide. Its core products include biochip array technology; clinical chemistry analyzers and reagents; quality controls; recombinant proteins and antibodies.

Related Links:

Randox



Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Mobile X-Ray System
K4W
VTE Prevention System
Flowtron ACS900
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The fiber in the brain implant is less than half a millimeter thick (Photo courtesy of Peter Aagaard Brixen)

Brain Implant Records Neural Signals and Delivers Precise Medication

Neurological diseases such as epilepsy involve complex interactions across multiple layers of the brain, yet current implants can typically stimulate or record activity from only a single point.... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.